An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective

Clinical trial NCT02566967 · COMPLETED

Trial details

NCT number

NCT02566967

Sponsor

Norman B. Gaylis, MD

Status

COMPLETED

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2015-05-01

Primary completion

2017-12-01

Enrollment

20

View on ClinicalTrials.gov